Back to search

Article

Glucagon-Like Peptide 1 Receptor Agonists and Cardiovascular Disease Risk: Findings from Real-World Data using AI-Powered Outcomes

2024-09-18

Abstract excerpt

<h4>ABSTRACT</h4> <h4>Background</h4> The SELECT trial showed cardiovascular benefits of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in obese patients with cardiovascular disease; however, real-world data (RWD) on this benefit remain limited. This study used an artificial intelligence (AI)-generated algorithm and multimodal RWD to evaluate the impact of GLP-1 RAs on cardiovascular disease risk in a popul...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
ddd825e5-df1d-5e80-b4a7-7b0723e53c20
DOI
10.1101/2024.09.17.24313797
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Glucagon-Like Peptide 1 Receptor Agonists and Cardiovascular Disease Risk: Findings from Real-World Data using AI-Powered OutcomesDOI 10.1101/2024.09.17.24313797
Cardiovascular Outcomes with GLP-1 Receptor Agonists in Patients with Type 2 Diabetes or Obesity Undergoing Surgical Aortic Valve ReplacementSemantic proximity
Comparative cardiovascular safety of GLP-1 receptor agonists versus other glucose-lowering agents in real-world patients with type 2 diabetes: a nationwide population-based cohort studySemantic proximity
Development and Multinational Validation of Artificial Intelligence-Enabled ASCVD Risk Stratification Using ElectrocardiogramsSemantic proximity
Cardiovascular Outcomes of Tirzepatide vs Semaglutide in Obesity Without Type 2 Diabetes: A Matched Cohort StudySemantic proximity
Comparative Effectiveness of Second-line Antihyperglycemic Agents for Cardiovascular Outcomes: A Large-scale, Multinational, Federated Analysis of the LEGEND-T2DM StudySemantic proximity
Liraglutide Use in A Real-World Setting: Patient Characteristics at Antidiabetic Treatment Initiation Modulate Cardiovascular Safety OutcomesSemantic proximity
AI-Driven Personalization of Dual Antiplatelet Therapy Duration Post-PCI: A Novel Approach Balancing Ischemic and Bleeding Risks in the UAE PopulationSemantic proximity
Effect of Renin-Angiotensin System (RAS) Inhibitors in Acute Ischemic Stroke to Improve Outcomes in In-Patient Settings: A Cross Sectional and Longitudinal AnalysisSemantic proximity
Multiomics Insight Into the Role of Glucagon-Like Peptide-1 Receptor Agonists in Heart FailureSemantic proximity
Emulating randomized controlled trials of long-acting insulins and cardiovascular events using real-world data for patients with type 2 diabetesSemantic proximity
Comparative cardiovascular effectiveness of glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors in atherosclerotic cardiovascular disease phenotypes: a systematic review and meta-analysis.Semantic proximity
Predicting the risks for stroke, cardiovascular disease, and peripheral vascular disease among people with type 2 diabetes with artificial intelligence models: a systematic review and meta-analysisSemantic proximity
Select a neighboring publication to make it the new centre.